Bupropion SR vs. placebo for weight loss in obese patients with depressive symptoms. - Wikidata - wikimedia - TriplyDB

Bupropion SR vs. placebo for weight loss in obese patients with depressive symptoms.

Bupropion SR vs. placebo for weight loss in obese patients with depressive symptoms.

http://www.wikidata.org/entity/Q44177213

about

15 years of clinical experience with bupropion HCl: from bupropion to bupropion SR to bupropion XL A Review of the Neuropharmacology of Bupropion, a Dual Norepinephrine and Dopamine Reuptake Inhibitor Naltrexone HCI/bupropion HCI for chronic weight management in obese adults: patient selection and perspectives Diabetes-associated depression: the serotonergic system as a novel multifunctional target Pharmacotherapy of Obesity: Clinical Trials to Clinical Practice.Extended-release bupropion: an antidepressant with a broad spectrum of therapeutic activity?Bupropion for overweight women with binge-eating disorder: a randomized, double-blind, placebo-controlled trial Sizing up pharmacotherapy for obesity The overlap between binge eating disorder and substance use disorders: Diagnosis and neurobiology.Bupropion versus sertraline in the treatment of depressive patients with binge eating disorder: retrospective cohort study.Current and investigational antiobesity agents and obesity therapeutic treatment targets.The effect of antidepressants on lipid homeostasis: a cardiac safety concern?A review of treating depression in diabetes: emerging findings.Weight loss with naltrexone SR/bupropion SR combination therapy as an adjunct to behavior modification: the COR-BMOD trial.Effect of comedication of bupropion and other antidepressants on body mass index.Emerging drugs for obesity: linking novel biological mechanisms to pharmaceutical pipelines.The effect of antidepressants on glucose homeostasis and insulin sensitivity: synthesis and mechanisms.Food reinforcement and eating: a multilevel analysis.Pharmacotherapy for childhood obesity: present and future prospects.Investigational therapies in the treatment of obesity.Bupropion for weight reduction.Long-Term Weight Change after Initiating Second-Generation Antidepressants.Pharmacotherapeutic options for overweight adolescents.Chronic dieting among extremely obese bariatric surgery candidates Outcomes in major depressive disorder: the evolving concept of remission and its implications for treatment.Changes in symptoms of depression with weight loss: results of a randomized trial.Naltrexone/Bupropion combination therapy in overweight or obese patients with major depressive disorder: results of a pilot study Drug-induced hyperphagia: what can we learn from psychiatric medications?Method-of-use study of naltrexone sustained release (SR)/bupropion SR on body weight in individuals with obesity.New drug targets for the treatment of obesity.Combination therapy with naltrexone and bupropion for obesity.Neuropsychiatric adverse effects of centrally acting antiobesity drugs.Drug safety evaluation of naltrexone/bupropion for the treatment of obesity.Bupropion-SR plus naltrexone-SR for the treatment of mild-to-moderate obesity.Managing comorbid obesity and depression through clinical pharmacotherapies.Superstition predicts favorable weight change in an open-placebo trial: a prospective study."Meaningful use" provides a meaningful opportunity.Comparative Effectiveness of Smoking Cessation Medications to Attenuate Weight Gain Following Cessation.Current pharmacotherapy for obesity.Acute behavioural effects of bupropion and naltrexone, alone and in combination, in non-deprived male rats presented with palatable mash.

P2860

Q24530904-B3ADACAE-2DFD-4A83-B5F3-940F64CF0F13 Q24563250-E02AD21F-9EF8-4B50-9277-EDCC4642F450 Q26746239-427108AD-482D-4815-9C31-FB83DE5DE873 Q26864574-2A7839BE-E45E-471A-B4E1-C573DDDDA8DF Q30400748-0909B3E0-F326-4207-BD51-D5DD0E955185 Q30442979-911344B4-4457-44C3-BC11-7EF9F6BE6FDF Q33615158-F993DF84-658E-4634-AFD6-97863C243FCA Q33969368-A487CC76-6AF1-4F28-A1DF-2C1D32A91615 Q34133292-1B202CA4-63CC-4F15-B12B-0400119C1FD2 Q34217281-DC1DC104-AFFC-4307-B2EB-0093F879D329 Q34344786-6919382D-0F6E-42FD-96AE-48E3B75764B4 Q34538100-9B2C00DE-47E6-4BBA-B7CE-4250B1F3CF6A Q34597335-C776D82A-75B1-4D77-8F2C-13D908645417 Q35695148-2F3BE7CD-E5EB-424F-8BD4-85BC292BCD28 Q35852531-F44C532B-8280-4A49-8E1E-CF1343BBB82E Q36219670-978F14FE-EC16-430A-BF86-283993546B17 Q36349761-9527BD83-0E8D-459C-A259-B5B927EA4E21 Q36416603-3DDA6265-3CE8-4654-B080-FA73BA0F6587 Q36468087-4DBD4B19-C76B-49F5-85AE-28640A8CAC51 Q36543067-4266DB92-9D5E-48F6-8CA7-F987F9B4FB40 Q36691753-4245B926-950C-42E3-8AB2-B157942070A2 Q36850510-1AA8C8C2-7D41-4032-945F-FDD9D5686736 Q36891391-476F39F9-A229-4982-98DE-F138641D1B77 Q36901008-E5290CF9-38BD-4B73-8CC7-88165D4BE31E Q37144258-9DA1B4DD-15FB-485B-AFC1-9068DC75A54E Q37171629-FA854F27-C0D4-429E-BA83-A67BC64F5D0C Q37226997-4A1A0038-3E58-4C17-9590-ECA8096FCBD9 Q37254782-8431921B-68F8-45E7-93E9-D3D626F6F23E Q37633367-35227551-8AB8-45A5-80BF-504CE2EBEB99 Q37886661-60B57EE3-C9E6-457C-B409-35235B6A1258 Q37891982-7845D65F-4ED6-4105-870F-B02F13DE53AC Q37939362-CDF9D9E9-F48E-4DC5-A458-F8E37FC218FD Q38207128-FFFDDC1B-8F56-4F79-B07B-D7821DBE7AD3 Q38619054-33096CBD-0C36-46B0-BCBE-74D1E0207C54 Q38859885-AD83C048-BD0C-42E7-BD0C-C082FEA20C83 Q39095202-E34EAC75-7A58-4D5A-A0B1-58F8A48C26AE Q42678465-0F01F2C1-B0B0-4CC4-9CF8-6697D5CD8B54 Q47316155-355A96AD-2258-4981-9D39-CBE33D5EEFC1 Q47899412-998F7DD4-42E3-4522-998A-FDB2058E1876 Q52638749-BB78EB62-B57A-4A71-BCA9-5FBC63E31AD0

P2860

Bupropion SR vs. placebo for weight loss in obese patients with depressive symptoms.

http://www.wikidata.org/entity/Q44177213

description

2002 nî lūn-bûn

@nan

2002年の論文

@ja

2002年学术文章

@wuu

2002年学术文章

@zh

2002年学术文章

@zh-cn

2002年学术文章

@zh-hans

2002年学术文章

@zh-my

2002年学术文章

@zh-sg

2002年學術文章

@yue

2002年學術文章

@zh-hant

name

Bupropion SR vs. placebo for weight loss in obese patients with depressive symptoms.

@en

Bupropion SR vs. placebo for weight loss in obese patients with depressive symptoms.

@nl

type

label

Bupropion SR vs. placebo for weight loss in obese patients with depressive symptoms.

@en

Bupropion SR vs. placebo for weight loss in obese patients with depressive symptoms.

@nl

prefLabel

Bupropion SR vs. placebo for weight loss in obese patients with depressive symptoms.

@en

Bupropion SR vs. placebo for weight loss in obese patients with depressive symptoms.

@nl

P1433

Q44177213-7C82C84E-84B1-4D9D-99E5-3C73F98E8DDB

P1476

Q44177213-CF77F8AC-18F8-476F-8473-90DE98F2D83E

P2093

Q44177213-2946C038-358E-4285-A0D8-8CA75935A57C

Q44177213-2D4688BA-F9C1-4995-B5BA-CFE856780A71

Q44177213-2FEF4749-E2DB-490A-84AA-6A990BB5F99E

Q44177213-44F75F93-B8B6-487B-A549-18A4569050D7

Q44177213-4A0728C4-3B15-4DC4-AE44-2C92E1CF0B20

Q44177213-4B754733-138C-4128-B2A9-F2382ACF2206

Q44177213-9CE32F94-1247-488C-8FB0-3A391EC408BB

Q44177213-BCAC80A5-5D63-4C5F-9EE7-F6B7E7456E9A

Q44177213-CE6A124A-372B-43FF-B97E-E069200C5777

Q44177213-F45FABD8-E1BA-4C5A-BB0F-087A4D03E321

P2860

Q44177213-01D55B7E-0B58-49BF-8E84-F7211306AB7E

Q44177213-173FD078-8527-45BE-A3C8-1A1E4AEBFD59

Q44177213-5BB5C0A0-32DF-4F45-B291-CDC85A055C0C

Q44177213-82F1CB35-AAE1-4FB0-A1CB-5F31D3786671

Q44177213-94A9DF28-A85C-408E-BBD7-FCD302B93F88

Q44177213-A84955EB-D610-4E28-A3A4-E8B1B911AF83

Q44177213-AEE76329-64BD-4424-9720-9015F4FB04EC

Q44177213-C2192C99-5B78-4092-9AC0-FABE7C0D72FA

Q44177213-DFF018BD-19F1-44A7-902D-4A989D59F7DB

Q44177213-ED9207E3-73CF-462B-BAC4-0F7BC428DDD9

P304

Q44177213-83E92A80-91B4-42F7-B9C7-0152B6B8C082

P31

Q44177213-FA8776E6-537C-4B76-A8D2-614CB4341055

P356

Q44177213-001C12FB-C362-4491-9851-3D18F669E57A

P433

Q44177213-982D8085-9829-484D-AB0E-F57C0EA96F7D

P478

Q44177213-E2D37101-A221-4422-AC3A-22BED26E5367

P50

Q44177213-E6A96DEC-6D7A-4E11-A48F-82FFD698F017

P577

Q44177213-6C9B2771-5A36-4131-96E1-89BD7AC2E054

P5875

Q44177213-BADB983A-26F0-437B-A03C-D710DD4ACA83

P698

Q44177213-CB02C3E9-7477-4547-A966-4D77A4154238

P921

Q44177213-3BB32717-D58E-4512-8D8A-7F509E8B503E

Q44177213-3BCA50F5-058A-42C0-8A92-940E0E286933

P356

P1433

P1476

Bupropion SR vs. placebo for weight loss in obese patients with depressive symptoms.

@en

P2093

Adesh K Jain

http://www.w3.org/2001/XMLSchema#string

Alan Metz

http://www.w3.org/2001/XMLSchema#string

Barbara Haight

http://www.w3.org/2001/XMLSchema#string

Brenda D Jamerson

http://www.w3.org/2001/XMLSchema#string

David B Allison

http://www.w3.org/2001/XMLSchema#string

Edwin R Brewer

http://www.w3.org/2001/XMLSchema#string

Kathleen S Buaron

http://www.w3.org/2001/XMLSchema#string

Kishore M Gadde

http://www.w3.org/2001/XMLSchema#string

Nathalie Richard

http://www.w3.org/2001/XMLSchema#string

Robert A Leadbetter

http://www.w3.org/2001/XMLSchema#string

P2860

A placebo-controlled comparison of the antidepressant efficacy and effects on sexual functioning of sustained-release bupropion and sertraline

Obesity and its comorbid conditions.

Dimensions of the Beck Depression Inventory-II in clinically depressed outpatients.

Neurochemical mechanism of action of anorectic drugs.

A neurochemical theory of appetite and weight changes in depressive states.

Bupropion for weight loss: an investigation of efficacy and tolerability in overweight and obese women.

Effect on body weight of bupropion sustained-release in patients with major depression treated for 52 weeks.

Bupropion SR enhances weight loss: a 48-week double-blind, placebo- controlled trial.

A controlled trial of sustained-release bupropion, a nicotine patch, or both for smoking cessation.

P304

1049-1056

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/OBY.2002.142

http://www.w3.org/2001/XMLSchema#string

P433

10

http://www.w3.org/2001/XMLSchema#string

P478

10

http://www.w3.org/2001/XMLSchema#string

P50

Thomas A Wadden

P577

2002-10-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

11082775

http://www.w3.org/2001/XMLSchema#string

P698

12376586

http://www.w3.org/2001/XMLSchema#string

P921